This large randomized trial found that percutaneous coronary intervention (PCI), when added as an initial treatment strategy to optimal medical therapy, does not reduce the risk of death, myocardial infarction (MI) or other major cardiovascular events in patients with stable coronary artery disease (CAD). This finding confirms those of a recent meta-analysis of previous smaller trials {1} comparing PCI to optimal medical therapy alone. Prevalence of angina was lower in the PCI group. However, freedom from angina increased in the medical treatment group as well, and the event rate was lower in this group during the follow-up period of 2.5-7 years than projected in the trial design. The authors speculate that these findings may reflect the effects of aggressive intervention for multiple risk factors and evidence-based use of medications. The study shows that PCI is not mandatory as an initial treatment in patients with stable angina. This finding may influence the perioperative management of patients with CAD who need non-cardiac surgery, although this specific setting was not investigated. The findings of the present study fit to those of a previous study that failed to find a beneficial effect of coronary artery revascularization before elective vascular surgery on long-term outcome {2}. Given the high incidence of cardiovascular complications when noncardiac surgery is performed after PCI {3}, these studies suggest that confinement to optimal medical therapy may be advisable in patients with stable coronary artery disease who need early noncardiac surgery.